SNGX - Soligenix secures European patent for Dusquetide's application in oral mucositis treatment

2023-05-16 09:11:17 ET

• Soligenix ( NASDAQ: SNGX ) had received a patent from the European Patent Office titled "Novel Peptides and Analogs for Treatment of Oral Mucositis."
• ( SNGX ) is trading ~3% higher premarket.
• This patent complements existing intellectual property in the United States, New Zealand, Japan, Australia, and Singapore, along with pending patent applications in various jurisdictions.
• The granted claims cover therapeutic applications of dusquetide (the active ingredient in SGX942) and related innate defense regulator ( IDR ) analogs. Furthermore, it adds to the composition of matter claims for dusquetide and related analogs previously issued worldwide.
• The therapeutic use claims are expected to be valid until 2034, the company said .

For further details see: